Setrobuvir Explained

Setrobuvir (also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015.^{[1] [2]} It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.^[2]

Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase.^[3]

Notes and References

1. Web site: Setrobuvir. AdisInsight. 28 August 2017. en.
2. Web site: HCV Followup: Anadys Acquired for Active Antiviral . October 24, 2011 . Chemical & Engineering News.
3. 19818610 . 2009 . Ruebsam . F . Murphy . DE . Tran . CV . Li . LS . Zhao . J . Dragovich . PS . McGuire . HM . Xiang . AX . Sun . Z . Ayida . Benjamin K. . Blazel . Julie K. . Kim . Sun Hee . Zhou . Yuefen . Han . Qing . Kissinger . Charles R. . Webber . Stephen E. . Showalter . Richard E. . Shah . Amit M. . Tsan . Mei . Patel . Rupal A. . Thompson . Peggy A. . Lebrun . Laurie A. . Hou . Huiying J. . Kamran . Ruhi . Sergeeva . Maria V. . Bartkowski . Darian M. . Nolan . Thomas G. . Norris . Daniel A. . Khandurina . Julia . Brooks . Jennifer . Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase . 19 . 22 . 6404–12 . 10.1016/j.bmcl.2009.09.045 . Bioorganic & Medicinal Chemistry Letters. 5870912 . 8 .